MrMumu的个人主页 - 老虎社区

MrMumu

MrMumu

暂无个人介绍

IP属地：未知

66关注

2粉丝

0主题

0勋章

2021-12-10

👍

Microsoft stock jumped more than 2% in morning trading

2021-12-10

Gg.com

Grab shares dropped another 9% in morning trading

2021-12-26

👍

2 Under-the-Radar Biotech Picks to Buy For The Long Haul

2021-12-10

Wow

Vaccine stocks dropped in morning trading

2021-12-25

👍👍

3 Charts to Consider if You Want to Own an EV Stock

2021-12-09

Gg.com

Grab stock dropped more than 6% in morning trading

2021-12-05

Nice sharing!

DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'

2021-12-05

👍👍

DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'

2021-12-28

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-12-28

Great ariticle, would you like to share it?

抱歉，原内容已删除

2021-12-27

Good read!

抱歉，原内容已删除

2021-12-26

Good read!

2 Under-the-Radar Biotech Picks to Buy For The Long Haul

2021-12-25

Great Read!

3 Charts to Consider if You Want to Own an EV Stock

2021-12-24

👍

抱歉，原内容已删除

2021-12-09

Ok!

3 Growth Stocks Down Over 50% To Buy Now

2021-12-05

Great sharing!

Peloton stock is a buy, but with an 'asterisk', analyst says

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3581994349439737","uuid":"3581994349439737","gmtCreate":1632620746524,"gmtModify":1638881999549,"name":"MrMumu","pinyin":"mrmumu","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":66,"tweetSize":16,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":696211249,"gmtCreate":1640701604587,"gmtModify":1640701625883,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696211249","repostId":"1146958718","repostType":4,"repost":{"id":"1146958718","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640698085,"share":"https://www.laohu8.com/m/news/1146958718?lang=&edition=full","pubTime":"2021-12-28 21:28","market":"us","language":"en","title":"10 Biggest Price Target Changes For Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1146958718","media":"Benzinga","summary":"Argus Research raised Tesla, Inc. TSLA +0% price target from $1,010 to $1,313. Tesla shares rose 1.8","content":"<p>Argus Research raised Tesla, Inc. TSLA +0% price target from $1,010 to $1,313. Tesla shares rose 1.8% to $1,113.84 in pre-market trading.</p>\n<p>Needham boosted the price target for Ciena Corporation CIEN +0.04% from $80 to $88. Ciena shares rose 0.1% to $77.25 in pre-market trading.</p>\n<p>Stifel raised MACOM Technology Solutions Holdings, Inc. MTSI +0% price target from $88 to $90. MACOM Technology shares gained 3.2% to close at $79.94 on Monday.</p>\n<p>HC Wainwright &amp; Co. cut BridgeBio Pharma, Inc. BBIO +0% price target from $88 to $24. BridgeBio Pharma shares rose 2.5% to $11.66 in pre-market trading.</p>\n<p>Needham raised the price target on F5, Inc. FFIV +0% from $265 to $303. F5shares rose 3.6% to close at $243.32 on Monday.</p>\n<p>Goldman Sachs lowered InnovAge Holding Corp. INNV +0% price target from $15 to $4. InnovAge Holding shares fell 1.5% to $4.64 in pre-market trading.</p>\n<p>Needham lifted the price target on Extreme Networks, Inc. EXTR +0% from $16 to $18.5. Extreme Networks shares gained 6% to $16.99 in pre-market trading.</p>\n<p>Argus Research boosted the price target on Hilton Worldwide Holdings Inc. HLT +0.01% from $162 to $178. Hilton Worldwide shares rose 0.3% to $155.72 in pre-market trading.</p>\n<p>Truist Securities reduced the price target for TrueCar, Inc. TRUE +0% from $6 to $4.25. TrueCar shares closed at $3.39 on Monday.</p>\n<p>Cowen &amp; Co. cut Valero Energy Corporation VLO +0.01% price target from $85 to $82. Valero Energy shares rose 0.5% to $73.50 in pre-market trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-28 21:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Argus Research raised Tesla, Inc. TSLA +0% price target from $1,010 to $1,313. Tesla shares rose 1.8% to $1,113.84 in pre-market trading.</p>\n<p>Needham boosted the price target for Ciena Corporation CIEN +0.04% from $80 to $88. Ciena shares rose 0.1% to $77.25 in pre-market trading.</p>\n<p>Stifel raised MACOM Technology Solutions Holdings, Inc. MTSI +0% price target from $88 to $90. MACOM Technology shares gained 3.2% to close at $79.94 on Monday.</p>\n<p>HC Wainwright &amp; Co. cut BridgeBio Pharma, Inc. BBIO +0% price target from $88 to $24. BridgeBio Pharma shares rose 2.5% to $11.66 in pre-market trading.</p>\n<p>Needham raised the price target on F5, Inc. FFIV +0% from $265 to $303. F5shares rose 3.6% to close at $243.32 on Monday.</p>\n<p>Goldman Sachs lowered InnovAge Holding Corp. INNV +0% price target from $15 to $4. InnovAge Holding shares fell 1.5% to $4.64 in pre-market trading.</p>\n<p>Needham lifted the price target on Extreme Networks, Inc. EXTR +0% from $16 to $18.5. Extreme Networks shares gained 6% to $16.99 in pre-market trading.</p>\n<p>Argus Research boosted the price target on Hilton Worldwide Holdings Inc. HLT +0.01% from $162 to $178. Hilton Worldwide shares rose 0.3% to $155.72 in pre-market trading.</p>\n<p>Truist Securities reduced the price target for TrueCar, Inc. TRUE +0% from $6 to $4.25. TrueCar shares closed at $3.39 on Monday.</p>\n<p>Cowen &amp; Co. cut Valero Energy Corporation VLO +0.01% price target from $85 to $82. Valero Energy shares rose 0.5% to $73.50 in pre-market trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FFIV":"F5 Inc","HLT":"希尔顿酒店","INNV":"InnovAge Holding Corp.","TSLA":"特斯拉","TRUE":"TrueCar, Inc.","VLO":"瓦莱罗能源","CIEN":"Ciena科技","BBIO":"BridgeBio Pharma, Inc.","MTSI":"MACOM Technology Solutions Holdings, Inc.","EXTR":"极速网络"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1146958718","content_text":"Argus Research raised Tesla, Inc. TSLA +0% price target from $1,010 to $1,313. Tesla shares rose 1.8% to $1,113.84 in pre-market trading.\nNeedham boosted the price target for Ciena Corporation CIEN +0.04% from $80 to $88. Ciena shares rose 0.1% to $77.25 in pre-market trading.\nStifel raised MACOM Technology Solutions Holdings, Inc. MTSI +0% price target from $88 to $90. MACOM Technology shares gained 3.2% to close at $79.94 on Monday.\nHC Wainwright & Co. cut BridgeBio Pharma, Inc. BBIO +0% price target from $88 to $24. BridgeBio Pharma shares rose 2.5% to $11.66 in pre-market trading.\nNeedham raised the price target on F5, Inc. FFIV +0% from $265 to $303. F5shares rose 3.6% to close at $243.32 on Monday.\nGoldman Sachs lowered InnovAge Holding Corp. INNV +0% price target from $15 to $4. InnovAge Holding shares fell 1.5% to $4.64 in pre-market trading.\nNeedham lifted the price target on Extreme Networks, Inc. EXTR +0% from $16 to $18.5. Extreme Networks shares gained 6% to $16.99 in pre-market trading.\nArgus Research boosted the price target on Hilton Worldwide Holdings Inc. HLT +0.01% from $162 to $178. Hilton Worldwide shares rose 0.3% to $155.72 in pre-market trading.\nTruist Securities reduced the price target for TrueCar, Inc. TRUE +0% from $6 to $4.25. TrueCar shares closed at $3.39 on Monday.\nCowen & Co. cut Valero Energy Corporation VLO +0.01% price target from $85 to $82. Valero Energy shares rose 0.5% to $73.50 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":2089,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696211019,"gmtCreate":1640701555641,"gmtModify":1640701555703,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696211019","repostId":"2194343800","repostType":4,"repost":{"id":"2194343800","kind":"highlight","pubTimestamp":1640700003,"share":"https://www.laohu8.com/m/news/2194343800?lang=&edition=full","pubTime":"2021-12-28 22:00","market":"us","language":"en","title":"Is PayPal Still a Buy After Falling 18% in 2021?","url":"https://stock-news.laohu8.com/highlight/detail?id=2194343800","media":"Motley Fool","summary":"The market's waning excitement for this digital-payments behemoth could be an investment opportunity.","content":"<p><b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b>&nbsp;(NASDAQ:PYPL), which has been at the forefront of digital payments for two decades, is not immune to the market's whims. Growing sales and profits aren't going to be enough to prevent the stock from finishing 2021 in the red.&nbsp;</p>\n<p>As is the case with pandemic winners like&nbsp;<b>Roku</b>,&nbsp;<b>Teledoc</b>, and&nbsp;<b><a href=\"https://laohu8.com/S/ZM\">Zoom</a></b>, investors have become pessimistic about PayPal's prospects&nbsp;in a post-pandemic world. Since hitting an all-time high of $308.53&nbsp;in July, PayPal's stock has dropped 38%.&nbsp;</p>\n<p>Is this&nbsp;fintech&nbsp;leader a buy after its poor performance in 2021?&nbsp;</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F658590%2Fgettyimages-1158779061.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"428\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h2>The market is pessimistic&nbsp;</h2>\n<p>During the most recent quarterly update, management's disappointing guidance certainly hurt the stock. Forecasts of fourth-quarter revenue of $6.9 billion (at the midpoint) and 2022 estimated sales of close to $30 billion weren't well-received by Wall Street.&nbsp;</p>\n<p>John Rainey, PayPal's CFO, admitted that coming up with a financial outlook in this environment is proving to be very challenging. \"If it weren't difficult enough to forecast with the reopening of the economy, we overlay <b><a href=\"https://laohu8.com/S/EBAY\">eBay</a> </b>on top of the supply chain issues and inflationary pressures and the impact that can have on our business. And it makes it very complex to forecast,\" he said on the Q3 earnings call.&nbsp;</p>\n<p>The extreme uncertainty in the economy today, propelled by the fast-spreading coronavirus omicron variant, definitely makes the near-term outlook unclear. Nevertheless, PayPal's revenue and net income continue marching higher with each passing quarter, making the stock's underperformance this year unwarranted.&nbsp;</p>\n<h2>PayPal is still dominating&nbsp;</h2>\n<p>I think it's best to take a step back and consider the bigger picture and long-term outlook for PayPal. The business has some positive developments working in its favor as we look ahead to 2022 and beyond.&nbsp;</p>\n<p>By being the pioneer of the digital-payments space for more than 20 years, this long history has resulted in massive scale. PayPal currently has 383 million active individual accounts and 33 million active merchant accounts on its platform. This huge user base is a significant competitive advantage. Perhaps even more remarkable is that PayPal processed a whopping $310 billion in total payment volume during the third quarter, up 26% year over year.&nbsp;</p>\n<p>PayPal is widely recognized as the leading payments brand when it comes to innovation in the industry. Earlier this year, the leadership team introduced an updated PayPal mobile app,&nbsp;with features like a full digital wallet, high-yield savings account, shopping deals and rewards, and bill pay. The functionality and ease of use is unmatched. Stock-trading&nbsp;capabilities are anticipated to be coming soon.&nbsp;</p>\n<p>The potential for new acquisitions and partnerships also provide a nice tailwind for the business. PayPal's recent purchase of Japanese buy now, pay later enterprise Paidy extends the company's reach to the world's third-largest e-commerce market that still conducts 70% of purchases with cash. Additionally, the recently announced&nbsp;partnership with&nbsp;Amazon will allow U.S. customers to use Venmo as a checkout option on the e-commerce juggernaut's website and mobile app.&nbsp;</p>\n<h2>Consider buying shares&nbsp;</h2>\n<p>Despite missing Wall Street's revenue estimates for two straight quarters, PayPal's numbers still look solid. The user base is growing rapidly, engagement keeps ticking up, and the innovative culture is robust. Let's also not forget just how profitable this business is, generating a 21% free cash flow&nbsp;margin&nbsp;in Q3.&nbsp;</p>\n<p>There are still a few trading days left, but 2021 is shaping up to be PayPal stock's first down year since it spun off and became a public company in July 2015. Nonetheless, it has produced a market-crushing return of more than 400% during that 6 1/2-year stretch. Even though the fundamentals remain intact, sentiment has soured on PayPal.&nbsp;</p>\n<p>Smart investors should view this as a fantastic opportunity to buy shares right now.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is PayPal Still a Buy After Falling 18% in 2021?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs PayPal Still a Buy After Falling 18% in 2021?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/28/is-paypal-still-a-buy-after-falling-in-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PayPal (NASDAQ:PYPL), which has been at the forefront of digital payments for two decades, is not immune to the market's whims. Growing sales and profits aren't going to be enough to prevent the stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/28/is-paypal-still-a-buy-after-falling-in-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4535":"淡马锡持仓","BK4551":"寇图资本持仓","BK4524":"宅经济概念","BK4527":"明星科技股","PYPL":"PayPal","BK4534":"瑞士信贷持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4566":"资本集团","BK4106":"数据处理与外包服务","BK4554":"元宇宙及AR概念"},"source_url":"https://www.fool.com/investing/2021/12/28/is-paypal-still-a-buy-after-falling-in-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2194343800","content_text":"PayPal (NASDAQ:PYPL), which has been at the forefront of digital payments for two decades, is not immune to the market's whims. Growing sales and profits aren't going to be enough to prevent the stock from finishing 2021 in the red. \nAs is the case with pandemic winners like Roku, Teledoc, and Zoom, investors have become pessimistic about PayPal's prospects in a post-pandemic world. Since hitting an all-time high of $308.53 in July, PayPal's stock has dropped 38%. \nIs this fintech leader a buy after its poor performance in 2021? \n\nImage source: Getty Images.\nThe market is pessimistic \nDuring the most recent quarterly update, management's disappointing guidance certainly hurt the stock. Forecasts of fourth-quarter revenue of $6.9 billion (at the midpoint) and 2022 estimated sales of close to $30 billion weren't well-received by Wall Street. \nJohn Rainey, PayPal's CFO, admitted that coming up with a financial outlook in this environment is proving to be very challenging. \"If it weren't difficult enough to forecast with the reopening of the economy, we overlay eBay on top of the supply chain issues and inflationary pressures and the impact that can have on our business. And it makes it very complex to forecast,\" he said on the Q3 earnings call. \nThe extreme uncertainty in the economy today, propelled by the fast-spreading coronavirus omicron variant, definitely makes the near-term outlook unclear. Nevertheless, PayPal's revenue and net income continue marching higher with each passing quarter, making the stock's underperformance this year unwarranted. \nPayPal is still dominating \nI think it's best to take a step back and consider the bigger picture and long-term outlook for PayPal. The business has some positive developments working in its favor as we look ahead to 2022 and beyond. \nBy being the pioneer of the digital-payments space for more than 20 years, this long history has resulted in massive scale. PayPal currently has 383 million active individual accounts and 33 million active merchant accounts on its platform. This huge user base is a significant competitive advantage. Perhaps even more remarkable is that PayPal processed a whopping $310 billion in total payment volume during the third quarter, up 26% year over year. \nPayPal is widely recognized as the leading payments brand when it comes to innovation in the industry. Earlier this year, the leadership team introduced an updated PayPal mobile app, with features like a full digital wallet, high-yield savings account, shopping deals and rewards, and bill pay. The functionality and ease of use is unmatched. Stock-trading capabilities are anticipated to be coming soon. \nThe potential for new acquisitions and partnerships also provide a nice tailwind for the business. PayPal's recent purchase of Japanese buy now, pay later enterprise Paidy extends the company's reach to the world's third-largest e-commerce market that still conducts 70% of purchases with cash. Additionally, the recently announced partnership with Amazon will allow U.S. customers to use Venmo as a checkout option on the e-commerce juggernaut's website and mobile app. \nConsider buying shares \nDespite missing Wall Street's revenue estimates for two straight quarters, PayPal's numbers still look solid. The user base is growing rapidly, engagement keeps ticking up, and the innovative culture is robust. Let's also not forget just how profitable this business is, generating a 21% free cash flow margin in Q3. \nThere are still a few trading days left, but 2021 is shaping up to be PayPal stock's first down year since it spun off and became a public company in July 2015. Nonetheless, it has produced a market-crushing return of more than 400% during that 6 1/2-year stretch. Even though the fundamentals remain intact, sentiment has soured on PayPal. \nSmart investors should view this as a fantastic opportunity to buy shares right now.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696935515,"gmtCreate":1640595274071,"gmtModify":1640595291523,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696935515","repostId":"1160732619","repostType":4,"isVote":1,"tweetType":1,"viewCount":1510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698707452,"gmtCreate":1640526563906,"gmtModify":1640526564008,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698707452","repostId":"2193173436","repostType":4,"repost":{"id":"2193173436","kind":"highlight","pubTimestamp":1640485553,"share":"https://www.laohu8.com/m/news/2193173436?lang=&edition=full","pubTime":"2021-12-26 10:25","market":"us","language":"en","title":"2 Under-the-Radar Biotech Picks to Buy For The Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193173436","media":"Motley Fool","summary":"These quiet biotechs are tightly focused and practically alone in their markets.","content":"<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest <i>downside</i> potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.</p>\n<p>Both companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.</p>\n<h2>1. Catalyst Pharmaceuticals</h2>\n<p><b>Catalyst Pharmaceuticals</b> (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.</p>\n<p>In the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might <a href=\"https://laohu8.com/S/AONE.U\">one</a> day be able to offer it to every LEMS patient in the world.</p>\n<p>Firdapse was originally licensed by Catalyst as part of a deal with <b>BioMarin Pharmaceutical</b>, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.</p>\n<p>So, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.</p>\n<h2>2. Corcept Therapeutics</h2>\n<p><b>Corcept Therapeutics</b> (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.</p>\n<p>Corcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.</p>\n<p>It's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.</p>\n<p>The company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.</p>\n<p>In the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Under-the-Radar Biotech Picks to Buy For The Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Under-the-Radar Biotech Picks to Buy For The Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CORT":"Corcept医疗","BK4211":"区域性银行","BK4139":"生物科技","CPRX":"Catalyst Pharmaceutical Partners","BK4532":"文艺复兴科技持仓","BK4007":"制药","FCF":"第一联邦金融"},"source_url":"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193173436","content_text":"It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest downside potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.\nBoth companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.\n1. Catalyst Pharmaceuticals\nCatalyst Pharmaceuticals (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.\nIn the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might one day be able to offer it to every LEMS patient in the world.\nFirdapse was originally licensed by Catalyst as part of a deal with BioMarin Pharmaceutical, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.\nSo, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.\n2. Corcept Therapeutics\nCorcept Therapeutics (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.\nCorcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.\nIt's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.\nThe company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.\nIn the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698707893,"gmtCreate":1640526505470,"gmtModify":1640526505470,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698707893","repostId":"2193173436","repostType":4,"repost":{"id":"2193173436","kind":"highlight","pubTimestamp":1640485553,"share":"https://www.laohu8.com/m/news/2193173436?lang=&edition=full","pubTime":"2021-12-26 10:25","market":"us","language":"en","title":"2 Under-the-Radar Biotech Picks to Buy For The Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193173436","media":"Motley Fool","summary":"These quiet biotechs are tightly focused and practically alone in their markets.","content":"<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest <i>downside</i> potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.</p>\n<p>Both companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.</p>\n<h2>1. Catalyst Pharmaceuticals</h2>\n<p><b>Catalyst Pharmaceuticals</b> (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.</p>\n<p>In the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might <a href=\"https://laohu8.com/S/AONE.U\">one</a> day be able to offer it to every LEMS patient in the world.</p>\n<p>Firdapse was originally licensed by Catalyst as part of a deal with <b>BioMarin Pharmaceutical</b>, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.</p>\n<p>So, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.</p>\n<h2>2. Corcept Therapeutics</h2>\n<p><b>Corcept Therapeutics</b> (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.</p>\n<p>Corcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.</p>\n<p>It's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.</p>\n<p>The company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.</p>\n<p>In the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Under-the-Radar Biotech Picks to Buy For The Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Under-the-Radar Biotech Picks to Buy For The Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CORT":"Corcept医疗","BK4211":"区域性银行","BK4139":"生物科技","CPRX":"Catalyst Pharmaceutical Partners","BK4532":"文艺复兴科技持仓","BK4007":"制药","FCF":"第一联邦金融"},"source_url":"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193173436","content_text":"It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest downside potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.\nBoth companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.\n1. Catalyst Pharmaceuticals\nCatalyst Pharmaceuticals (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.\nIn the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might one day be able to offer it to every LEMS patient in the world.\nFirdapse was originally licensed by Catalyst as part of a deal with BioMarin Pharmaceutical, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.\nSo, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.\n2. Corcept Therapeutics\nCorcept Therapeutics (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.\nCorcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.\nIt's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.\nThe company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.\nIn the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698597070,"gmtCreate":1640439401589,"gmtModify":1640439401696,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698597070","repostId":"1122704248","repostType":4,"repost":{"id":"1122704248","kind":"news","pubTimestamp":1640346833,"share":"https://www.laohu8.com/m/news/1122704248?lang=&edition=full","pubTime":"2021-12-24 19:53","market":"us","language":"en","title":"3 Charts to Consider if You Want to Own an EV Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1122704248","media":"Motley Fool","summary":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some","content":"<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.</p>\n<p>Beyond just looking at the exciting new products and potentially huge market,investors should research&nbsp;details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.</p>\n<p><b>Returns have been unpredictable</b></p>\n<p>Many have bought into the EV sector looking for large, market-beating returns. While shares of EV leader<b>Tesla</b>(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/628cf15ff39a9f1a896ba56a7db9020d\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>DATA BYYCHARTS.</span></p>\n<p>Even the strong returns from Tesla and&nbsp;<b>Lucid Group</b>(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.<b>Lordstown Motors</b>(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.</p>\n<p><b>There's plenty of demand</b></p>\n<p>Just looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a2201193c16f33bc21f52f5aacebbea\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.</span></p>\n<p>Tesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent&nbsp;market capitalizations&nbsp;of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.</p>\n<p><b>Profitability will take time</b></p>\n<p>Investors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32eab03a7b97ed8deb8757e127924d51\" tg-width=\"700\" tg-height=\"495\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.</span></p>\n<p>Tesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .</p>\n<p>BYD is perhaps a less well-known Chinese EV company, and it sells more than just&nbsp;electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.</p>\n<p>Lucid and&nbsp;<b>Rivian Automotive</b>(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Charts to Consider if You Want to Own an EV Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Charts to Consider if You Want to Own an EV Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 19:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏汽车","LCID":"Lucid Group Inc","TSLA":"特斯拉","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122704248","content_text":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.\nBeyond just looking at the exciting new products and potentially huge market,investors should research details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.\nReturns have been unpredictable\nMany have bought into the EV sector looking for large, market-beating returns. While shares of EV leaderTesla(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:\nDATA BYYCHARTS.\nEven the strong returns from Tesla and Lucid Group(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers Nio(NYSE:NIO) and XPeng(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.Lordstown Motors(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.\nThere's plenty of demand\nJust looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.\nTesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent market capitalizations of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.\nProfitability will take time\nInvestors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.\nTesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .\nBYD is perhaps a less well-known Chinese EV company, and it sells more than just electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.\nLucid and Rivian Automotive(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698594486,"gmtCreate":1640439305692,"gmtModify":1640439305763,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great Read!","listText":"Great Read!","text":"Great Read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698594486","repostId":"1122704248","repostType":4,"repost":{"id":"1122704248","kind":"news","pubTimestamp":1640346833,"share":"https://www.laohu8.com/m/news/1122704248?lang=&edition=full","pubTime":"2021-12-24 19:53","market":"us","language":"en","title":"3 Charts to Consider if You Want to Own an EV Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1122704248","media":"Motley Fool","summary":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some","content":"<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.</p>\n<p>Beyond just looking at the exciting new products and potentially huge market,investors should research&nbsp;details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.</p>\n<p><b>Returns have been unpredictable</b></p>\n<p>Many have bought into the EV sector looking for large, market-beating returns. While shares of EV leader<b>Tesla</b>(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/628cf15ff39a9f1a896ba56a7db9020d\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>DATA BYYCHARTS.</span></p>\n<p>Even the strong returns from Tesla and&nbsp;<b>Lucid Group</b>(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.<b>Lordstown Motors</b>(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.</p>\n<p><b>There's plenty of demand</b></p>\n<p>Just looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a2201193c16f33bc21f52f5aacebbea\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.</span></p>\n<p>Tesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent&nbsp;market capitalizations&nbsp;of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.</p>\n<p><b>Profitability will take time</b></p>\n<p>Investors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32eab03a7b97ed8deb8757e127924d51\" tg-width=\"700\" tg-height=\"495\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.</span></p>\n<p>Tesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .</p>\n<p>BYD is perhaps a less well-known Chinese EV company, and it sells more than just&nbsp;electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.</p>\n<p>Lucid and&nbsp;<b>Rivian Automotive</b>(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Charts to Consider if You Want to Own an EV Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Charts to Consider if You Want to Own an EV Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 19:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏汽车","LCID":"Lucid Group Inc","TSLA":"特斯拉","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122704248","content_text":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.\nBeyond just looking at the exciting new products and potentially huge market,investors should research details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.\nReturns have been unpredictable\nMany have bought into the EV sector looking for large, market-beating returns. While shares of EV leaderTesla(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:\nDATA BYYCHARTS.\nEven the strong returns from Tesla and Lucid Group(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers Nio(NYSE:NIO) and XPeng(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.Lordstown Motors(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.\nThere's plenty of demand\nJust looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.\nTesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent market capitalizations of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.\nProfitability will take time\nInvestors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.\nTesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .\nBYD is perhaps a less well-known Chinese EV company, and it sells more than just electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.\nLucid and Rivian Automotive(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698847627,"gmtCreate":1640353060903,"gmtModify":1640353060977,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698847627","repostId":"1103939939","repostType":4,"repost":{"id":"1103939939","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640331648,"share":"https://www.laohu8.com/m/news/1103939939?lang=&edition=full","pubTime":"2021-12-24 15:40","market":"us","language":"en","title":"Is JD.com's Stock Overvalued Or Undervalued?","url":"https://stock-news.laohu8.com/highlight/detail?id=1103939939","media":"Benzinga","summary":"JD.Com Inc (NASDAQ:JD) shares have lagged the S&P 500 in 2021, generating a year-to-date total retur","content":"<p><b>JD.Com Inc</b>&nbsp;(NASDAQ:JD) shares have lagged the S&amp;P 500 in 2021, generating a year-to-date total return loss of 16.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/348fb6f16daa57bc0b2b74aa73f08e1a\" tg-width=\"720\" tg-height=\"378\" width=\"100%\" height=\"auto\"><span>Photo: courtesy of JD</span></p>\n<p>JD's&nbsp;stock has had a wild ride in 2021, but investors may be wondering whether there’s any value in JD.com shares after the recent pullback.</p>\n<p><b>Earnings:</b>A price-to-earnings ratio (PE) is one of the most basic fundamental metrics for gauging a stock’s value. The lower the PE, the higher the value.</p>\n<p>For comparison, the S&amp;P 500’s PE is currently at about 28.7, nearly double its long-term average of 15.9.<b>JD.com’s PE is 29.1, roughly in-line with the S&amp;P 500 average as a whole</b>.</p>\n<p><b>Growth:</b>Looking ahead to the next four quarters, the S&amp;P 500's forward PE ratio looks much more reasonable at just 20.8.<b>JD.com’s forward earnings multiple of 5.4 is still less than a third the S&amp;P 500’s, making JD.com look undervalued</b>. JD.com’s forward PE ratio is also only about 17% of the average multiple of its consumer discretionary peers, which are averaging a 31.7 forward earnings multiple.</p>\n<p>Yet when it comes to evaluating a stock, earnings aren't everything.</p>\n<p>The growth rate is also critical for companies that are rapidly building their bottom lines. The price-to-earnings-to-growth ratio (PEG) is a good way to incorporate growth rates into the evaluation process.</p>\n<p>The S&amp;P 500’s overall PEG is currently about 1.0; JD.com’s PEG is 1.23, about 23% higher than the S&amp;P 500.</p>\n<p>Price-to-sales ratio is another important valuation metric, particularly for unprofitable companies and growth stocks. The S&amp;P 500’s PS ratio is currently 3.11, well above its long-term average of 1.63. JD.com’s PS ratio is 0.86, less than a third of the S&amp;P 500 average as a whole. JD.com's PS ratio is also down 22.3% over the last five years, suggesting the stock is priced at the low end of its historical valuation range.</p>\n<p>Finally, Wall Street analysts see value in JD.com stock over the next 12 months.<b>The average analyst price target among the 41 analysts covering JD.com is $105.19, suggesting 57.1% upside from current levels.</b></p>\n<p><b>The Verdict:</b>At its current price, JD.com stock appears to be extremely undervalued based on a sampling of common fundamental valuation metrics.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is JD.com's Stock Overvalued Or Undervalued?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs JD.com's Stock Overvalued Or Undervalued?\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-24 15:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>JD.Com Inc</b>&nbsp;(NASDAQ:JD) shares have lagged the S&amp;P 500 in 2021, generating a year-to-date total return loss of 16.1%.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/348fb6f16daa57bc0b2b74aa73f08e1a\" tg-width=\"720\" tg-height=\"378\" width=\"100%\" height=\"auto\"><span>Photo: courtesy of JD</span></p>\n<p>JD's&nbsp;stock has had a wild ride in 2021, but investors may be wondering whether there’s any value in JD.com shares after the recent pullback.</p>\n<p><b>Earnings:</b>A price-to-earnings ratio (PE) is one of the most basic fundamental metrics for gauging a stock’s value. The lower the PE, the higher the value.</p>\n<p>For comparison, the S&amp;P 500’s PE is currently at about 28.7, nearly double its long-term average of 15.9.<b>JD.com’s PE is 29.1, roughly in-line with the S&amp;P 500 average as a whole</b>.</p>\n<p><b>Growth:</b>Looking ahead to the next four quarters, the S&amp;P 500's forward PE ratio looks much more reasonable at just 20.8.<b>JD.com’s forward earnings multiple of 5.4 is still less than a third the S&amp;P 500’s, making JD.com look undervalued</b>. JD.com’s forward PE ratio is also only about 17% of the average multiple of its consumer discretionary peers, which are averaging a 31.7 forward earnings multiple.</p>\n<p>Yet when it comes to evaluating a stock, earnings aren't everything.</p>\n<p>The growth rate is also critical for companies that are rapidly building their bottom lines. The price-to-earnings-to-growth ratio (PEG) is a good way to incorporate growth rates into the evaluation process.</p>\n<p>The S&amp;P 500’s overall PEG is currently about 1.0; JD.com’s PEG is 1.23, about 23% higher than the S&amp;P 500.</p>\n<p>Price-to-sales ratio is another important valuation metric, particularly for unprofitable companies and growth stocks. The S&amp;P 500’s PS ratio is currently 3.11, well above its long-term average of 1.63. JD.com’s PS ratio is 0.86, less than a third of the S&amp;P 500 average as a whole. JD.com's PS ratio is also down 22.3% over the last five years, suggesting the stock is priced at the low end of its historical valuation range.</p>\n<p>Finally, Wall Street analysts see value in JD.com stock over the next 12 months.<b>The average analyst price target among the 41 analysts covering JD.com is $105.19, suggesting 57.1% upside from current levels.</b></p>\n<p><b>The Verdict:</b>At its current price, JD.com stock appears to be extremely undervalued based on a sampling of common fundamental valuation metrics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"09618":"京东集团-SW","JD":"京东"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1103939939","content_text":"JD.Com Inc (NASDAQ:JD) shares have lagged the S&P 500 in 2021, generating a year-to-date total return loss of 16.1%.\nPhoto: courtesy of JD\nJD's stock has had a wild ride in 2021, but investors may be wondering whether there’s any value in JD.com shares after the recent pullback.\nEarnings:A price-to-earnings ratio (PE) is one of the most basic fundamental metrics for gauging a stock’s value. The lower the PE, the higher the value.\nFor comparison, the S&P 500’s PE is currently at about 28.7, nearly double its long-term average of 15.9.JD.com’s PE is 29.1, roughly in-line with the S&P 500 average as a whole.\nGrowth:Looking ahead to the next four quarters, the S&P 500's forward PE ratio looks much more reasonable at just 20.8.JD.com’s forward earnings multiple of 5.4 is still less than a third the S&P 500’s, making JD.com look undervalued. JD.com’s forward PE ratio is also only about 17% of the average multiple of its consumer discretionary peers, which are averaging a 31.7 forward earnings multiple.\nYet when it comes to evaluating a stock, earnings aren't everything.\nThe growth rate is also critical for companies that are rapidly building their bottom lines. The price-to-earnings-to-growth ratio (PEG) is a good way to incorporate growth rates into the evaluation process.\nThe S&P 500’s overall PEG is currently about 1.0; JD.com’s PEG is 1.23, about 23% higher than the S&P 500.\nPrice-to-sales ratio is another important valuation metric, particularly for unprofitable companies and growth stocks. The S&P 500’s PS ratio is currently 3.11, well above its long-term average of 1.63. JD.com’s PS ratio is 0.86, less than a third of the S&P 500 average as a whole. JD.com's PS ratio is also down 22.3% over the last five years, suggesting the stock is priced at the low end of its historical valuation range.\nFinally, Wall Street analysts see value in JD.com stock over the next 12 months.The average analyst price target among the 41 analysts covering JD.com is $105.19, suggesting 57.1% upside from current levels.\nThe Verdict:At its current price, JD.com stock appears to be extremely undervalued based on a sampling of common fundamental valuation metrics.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605630262,"gmtCreate":1639150134852,"gmtModify":1639150181825,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605630262","repostId":"1148141788","repostType":4,"repost":{"id":"1148141788","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639147224,"share":"https://www.laohu8.com/m/news/1148141788?lang=&edition=full","pubTime":"2021-12-10 22:40","market":"us","language":"en","title":"Vaccine stocks dropped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1148141788","media":"Tiger Newspress","summary":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","content":"<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks dropped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks dropped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148141788","content_text":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605630899,"gmtCreate":1639150117311,"gmtModify":1639150239790,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Gg.com","listText":"Gg.com","text":"Gg.com","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605630899","repostId":"1134450838","repostType":4,"repost":{"id":"1134450838","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639148939,"share":"https://www.laohu8.com/m/news/1134450838?lang=&edition=full","pubTime":"2021-12-10 23:08","market":"us","language":"en","title":"Grab shares dropped another 9% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1134450838","media":"Tiger Newspress","summary":"Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.","content":"<p>Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/963eb8dd73ce8daa0d852d63f0bcc276\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab shares dropped another 9% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab shares dropped another 9% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/963eb8dd73ce8daa0d852d63f0bcc276\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134450838","content_text":"Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605697799,"gmtCreate":1639150093330,"gmtModify":1639150180726,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605697799","repostId":"1173242614","repostType":4,"repost":{"id":"1173242614","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639149896,"share":"https://www.laohu8.com/m/news/1173242614?lang=&edition=full","pubTime":"2021-12-10 23:24","market":"us","language":"en","title":"Microsoft stock jumped more than 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1173242614","media":"Tiger Newspress","summary":"Microsoft stock jumped more than 2% in morning trading as Microsoft set to win EU antitrust nod for ","content":"<p>Microsoft stock jumped more than 2% in morning trading&nbsp;as&nbsp;Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.</p>\n<p><img src=\"https://static.tigerbbs.com/f2b1206ee31bbf82c8f0f2186cf1d5d0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>U.S. software giant Microsoft Corp&nbsp;is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.</p>\n<p>The deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.</p>\n<p>Microsoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.</p>\n<p>The U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.</p>\n<p>The European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.</p>\n<p>The company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.</p>\n<p>The deal has already received the regulatory green light in the United States and Australia, without remedies given.</p>\n<p>Nuance, known for pioneering speech technology and helping launch Apple Inc's&nbsp;virtual assistant, Siri, serves 77% of U.S. hospitals.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft stock jumped more than 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft stock jumped more than 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Microsoft stock jumped more than 2% in morning trading&nbsp;as&nbsp;Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.</p>\n<p><img src=\"https://static.tigerbbs.com/f2b1206ee31bbf82c8f0f2186cf1d5d0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>U.S. software giant Microsoft Corp&nbsp;is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.</p>\n<p>The deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.</p>\n<p>Microsoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.</p>\n<p>The U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.</p>\n<p>The European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.</p>\n<p>The company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.</p>\n<p>The deal has already received the regulatory green light in the United States and Australia, without remedies given.</p>\n<p>Nuance, known for pioneering speech technology and helping launch Apple Inc's&nbsp;virtual assistant, Siri, serves 77% of U.S. hospitals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173242614","content_text":"Microsoft stock jumped more than 2% in morning trading as Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.\n\nU.S. software giant Microsoft Corp is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.\nThe deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.\nMicrosoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.\nThe U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.\nThe European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.\nThe company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.\nThe deal has already received the regulatory green light in the United States and Australia, without remedies given.\nNuance, known for pioneering speech technology and helping launch Apple Inc's virtual assistant, Siri, serves 77% of U.S. hospitals.","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602731338,"gmtCreate":1639064385388,"gmtModify":1639065338695,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Gg.com","listText":"Gg.com","text":"Gg.com","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602731338","repostId":"1196130142","repostType":4,"repost":{"id":"1196130142","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639062546,"share":"https://www.laohu8.com/m/news/1196130142?lang=&edition=full","pubTime":"2021-12-09 23:09","market":"us","language":"en","title":"Grab stock dropped more than 6% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1196130142","media":"Tiger Newspress","summary":"Grab Holdings stock dropped more than 6% in morning trading.","content":"<p>Grab Holdings stock dropped more than 6% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1c84529a60ffcf4e7ba53b126b147d9\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab stock dropped more than 6% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab stock dropped more than 6% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-09 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab Holdings stock dropped more than 6% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1c84529a60ffcf4e7ba53b126b147d9\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196130142","content_text":"Grab Holdings stock dropped more than 6% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602739367,"gmtCreate":1639064215751,"gmtModify":1639064832446,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Ok!","listText":"Ok!","text":"Ok!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602739367","repostId":"2189667447","repostType":2,"repost":{"id":"2189667447","kind":"highlight","pubTimestamp":1639022040,"share":"https://www.laohu8.com/m/news/2189667447?lang=&edition=full","pubTime":"2021-12-09 11:54","market":"us","language":"en","title":"3 Growth Stocks Down Over 50% To Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2189667447","media":"Motley Fool","summary":"The stock market is offering long-term investors an opportunity to buy these excellent businesses at a discount.","content":"<p>Investing in stocks for the long term can be an effective way to build wealth. However, the path to increasing stock values is rarely an upward straight line. More frequently, it is charted with several peaks and valleys. Long-term investors with the courage and discipline to hold or buy stocks during major crashes are sometimes rewarded with exponential gains.</p>\n<p>If you have extra cash you will not need for several years for life's necessities, you can buy stocks with good long-term prospects that are down due to short-term causes. <b>Chegg</b> (NYSE:CHGG), <b>Peloton</b> (NASDAQ:PTON), and <b>Skillz</b> (NYSE:SKLZ) are three stocks you can buy right now that are down over 50% while their long-term prospects remain intact.</p>\n<h2>Chegg</h2>\n<p>Chegg is an education technology company with a subscription business model. It caters primarily to college students by offering help with course curriculum. Chegg's platform has over 70 million step-by-step solutions to answers that students may have difficulty understanding. Chegg has built this database through student requests. In addition to having full access to existing content, students can ask 20 questions per month answered by subject-matter experts with their subscription. These questions and answers are then added to the database for all students to view.</p>\n<p>That's a lucrative business model because Chegg pays for that content once and gets the benefits for several years. The college curriculum does not change much over the years, so the assets pay dividends for decades. Chegg is already starting to capture the benefits of scaling to a more significant subscriber and revenue base. Indeed, from 2015 to 2020, operating profit grew from a loss of $57 million to a positive $57 million.</p>\n<p>Nevertheless, the stock is down 67.5% in 2021, with most losses coming after Nov. 1. That's when the company lowered the forecast for the rest of the fiscal year, citing a significant drop-off in student enrollment.</p>\n<h2>Peloton</h2>\n<p>Peloton sells interactive exercise equipment and a subscription to live and recorded exercise classes. The company was already gaining popularity before the pandemic increased the demand for in-home exercise equipment. As a result, revenue more than doubled to $4 billion in fiscal 2021.</p>\n<p>Once a customer signs up, they tend to stick around. Peloton boasted a membership retention rate of 92% in its most recent quarter ended Sept. 30. The company has a robust selection of live and recorded classes and makes members feel part of a community.</p>\n<p>Peloton had 2.5 million connected fitness subscribers at the end of the quarter, and management is forecasting that it will grow to 3.4 million by the end of fiscal 2022. Still, that would be a small part of the number of people that regularly exercise -- leaving Peloton with a long runway for growth.</p>\n<p>Peloton's stock is down 72% in 2021, mainly because economic reopening slowed the demand for in-home exercise equipment. That being said, Peloton's sales are growing on top of last years' elevated levels.</p>\n<h2>Skillz</h2>\n<p>Skillz is a gaming company with a unique twist: It allows contestants to wager on their games and doles out cash prizes to winners. The company's business is not considered gambling because the games on its site are based on skill. In other words, winners win because they are better at the game and not because of chance. Of course, if you have money on the line, you engage with the games more seriously than you would otherwise.</p>\n<p>In its most recent quarter,&nbsp;the company boasted 0.51 million monthly active users, up from 0.35 million in the year before. Still, the growth is not pleasing investors because the company is spending so heavily on sales and marketing. Skillz spent 112% of revenue on sales and marketing in its most recent quarter. Investors feel it should be getting better results from that spending. The stock is down 57.8% in 2021.</p>\n<p>Each of these three stocks is down big because of short-term catalysts. That could be an excellent buying opportunity for long-term investors who want to buy these growth stocks at more than 50% off their highs.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks Down Over 50% To Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks Down Over 50% To Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 11:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/08/3-growth-stocks-down-over-50-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in stocks for the long term can be an effective way to build wealth. However, the path to increasing stock values is rarely an upward straight line. More frequently, it is charted with ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/08/3-growth-stocks-down-over-50-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHGG":"Chegg Inc","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","SKLZ":"Skillz Inc","BK4204":"教育服务","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","PTON":"Peloton Interactive, Inc.","BK4085":"互动家庭娱乐","BK4190":"消闲用品"},"source_url":"https://www.fool.com/investing/2021/12/08/3-growth-stocks-down-over-50-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189667447","content_text":"Investing in stocks for the long term can be an effective way to build wealth. However, the path to increasing stock values is rarely an upward straight line. More frequently, it is charted with several peaks and valleys. Long-term investors with the courage and discipline to hold or buy stocks during major crashes are sometimes rewarded with exponential gains.\nIf you have extra cash you will not need for several years for life's necessities, you can buy stocks with good long-term prospects that are down due to short-term causes. Chegg (NYSE:CHGG), Peloton (NASDAQ:PTON), and Skillz (NYSE:SKLZ) are three stocks you can buy right now that are down over 50% while their long-term prospects remain intact.\nChegg\nChegg is an education technology company with a subscription business model. It caters primarily to college students by offering help with course curriculum. Chegg's platform has over 70 million step-by-step solutions to answers that students may have difficulty understanding. Chegg has built this database through student requests. In addition to having full access to existing content, students can ask 20 questions per month answered by subject-matter experts with their subscription. These questions and answers are then added to the database for all students to view.\nThat's a lucrative business model because Chegg pays for that content once and gets the benefits for several years. The college curriculum does not change much over the years, so the assets pay dividends for decades. Chegg is already starting to capture the benefits of scaling to a more significant subscriber and revenue base. Indeed, from 2015 to 2020, operating profit grew from a loss of $57 million to a positive $57 million.\nNevertheless, the stock is down 67.5% in 2021, with most losses coming after Nov. 1. That's when the company lowered the forecast for the rest of the fiscal year, citing a significant drop-off in student enrollment.\nPeloton\nPeloton sells interactive exercise equipment and a subscription to live and recorded exercise classes. The company was already gaining popularity before the pandemic increased the demand for in-home exercise equipment. As a result, revenue more than doubled to $4 billion in fiscal 2021.\nOnce a customer signs up, they tend to stick around. Peloton boasted a membership retention rate of 92% in its most recent quarter ended Sept. 30. The company has a robust selection of live and recorded classes and makes members feel part of a community.\nPeloton had 2.5 million connected fitness subscribers at the end of the quarter, and management is forecasting that it will grow to 3.4 million by the end of fiscal 2022. Still, that would be a small part of the number of people that regularly exercise -- leaving Peloton with a long runway for growth.\nPeloton's stock is down 72% in 2021, mainly because economic reopening slowed the demand for in-home exercise equipment. That being said, Peloton's sales are growing on top of last years' elevated levels.\nSkillz\nSkillz is a gaming company with a unique twist: It allows contestants to wager on their games and doles out cash prizes to winners. The company's business is not considered gambling because the games on its site are based on skill. In other words, winners win because they are better at the game and not because of chance. Of course, if you have money on the line, you engage with the games more seriously than you would otherwise.\nIn its most recent quarter, the company boasted 0.51 million monthly active users, up from 0.35 million in the year before. Still, the growth is not pleasing investors because the company is spending so heavily on sales and marketing. Skillz spent 112% of revenue on sales and marketing in its most recent quarter. Investors feel it should be getting better results from that spending. The stock is down 57.8% in 2021.\nEach of these three stocks is down big because of short-term catalysts. That could be an excellent buying opportunity for long-term investors who want to buy these growth stocks at more than 50% off their highs.","news_type":1},"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608667276,"gmtCreate":1638717131616,"gmtModify":1638756438111,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great sharing!","listText":"Great sharing!","text":"Great sharing!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608667276","repostId":"2189576203","repostType":4,"repost":{"id":"2189576203","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638691560,"share":"https://www.laohu8.com/m/news/2189576203?lang=&edition=full","pubTime":"2021-12-05 16:06","market":"us","language":"en","title":"Peloton stock is a buy, but with an 'asterisk', analyst says","url":"https://stock-news.laohu8.com/highlight/detail?id=2189576203","media":"Dow Jones","summary":"Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's","content":"<p>Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's stock is worth owning for investors with 'patience'</p>\n<p>Investors should buy Peloton Interactive Inc.'s stock, says Deutsche Bank analyst Chris Woronka, but only those who have the patience to ride out potential volatility, which could last a \"few quarters.\"</p>\n<p>The at-home fitness company's stock <a href=\"https://laohu8.com/S/PTON\">$(PTON)$</a> slumped 2.0% to close Monday at $43.55, reversing an earlier intraday gain of as much as 4.6%.</p>\n<p>Peloton was viewed as a hot COVID-19-pandemic play last year, with the stock rocketing more than fivefold (up 434%), as gym closures fueled an explosion in the \"work-in\" trend. It's been an entirely different play in 2021, however, as the stock has plunged 71% year to date. It closed Wednesday at $42.25, the lowest price since May 27, 2020.</p>\n<p>In comparison, shares of fitness center operator <a href=\"https://laohu8.com/S/PLNT\">Planet Fitness Inc</a>. (PLNT) have gained 3.8% this year and the S&amp;P 500 index has rallied 21%.</p>\n<p>While the stock has suffered a \"tough ride\" this year, and the going could still be a bit rough for a while, Deutsche Bank's Woronka said he is bullish on Peloton's fundamentals over the longer term.</p>\n<p>He initiated coverage of Peloton with a buy rating and a 12-month stock price target of $76, which implies nearly about 75% upside from current levels. Woronka said his view is based on an \"unemotional analysis\" of the company's earnings power in a \"normalized, fully-reopened\" economic environment.</p>\n<p>\"[W]hile it's never fun to lead off a buy report with a 'patience required' asterisk of sorts, that's exactly what we find ourselves doing here,\" Woronka wrote in a note to clients.</p>\n<p>As a fundamental analyst, Woronka said he is most interested in looking for \"asymmetrical risk/reward scenarios,\" and that's what he believes Pelton's stock provides at current levels. While there are scenarios in which the stock can still go lower, he believes there are more scenarios that result in even greater upside.</p>\n<p>\"Right now, we believe the market is looking at fitness stocks as an 'either/or' sector; either consumers stay at home to work out or they go back to their favorite pre-COVID-19 fitness facility,\" Woronka wrote. \"In our opinion, that's an oversimplified view of the world; we think the hybrid work model extends to fitness, too, and that [Peloton] has plenty of momentum to regain operationally.\"</p>\n<p>He realizes that sentiment on the stock isn't likely to reflect his bullish view \"until a few quarters of improved execution\" are in the books. But that's where the opportunity for reward lies over a 12-month time horizon.</p>\n<p>Once the stock starts trading on fundamentals again, Woronka believes \"it has quite a bit of room to run.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peloton stock is a buy, but with an 'asterisk', analyst says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeloton stock is a buy, but with an 'asterisk', analyst says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-05 16:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's stock is worth owning for investors with 'patience'</p>\n<p>Investors should buy Peloton Interactive Inc.'s stock, says Deutsche Bank analyst Chris Woronka, but only those who have the patience to ride out potential volatility, which could last a \"few quarters.\"</p>\n<p>The at-home fitness company's stock <a href=\"https://laohu8.com/S/PTON\">$(PTON)$</a> slumped 2.0% to close Monday at $43.55, reversing an earlier intraday gain of as much as 4.6%.</p>\n<p>Peloton was viewed as a hot COVID-19-pandemic play last year, with the stock rocketing more than fivefold (up 434%), as gym closures fueled an explosion in the \"work-in\" trend. It's been an entirely different play in 2021, however, as the stock has plunged 71% year to date. It closed Wednesday at $42.25, the lowest price since May 27, 2020.</p>\n<p>In comparison, shares of fitness center operator <a href=\"https://laohu8.com/S/PLNT\">Planet Fitness Inc</a>. (PLNT) have gained 3.8% this year and the S&amp;P 500 index has rallied 21%.</p>\n<p>While the stock has suffered a \"tough ride\" this year, and the going could still be a bit rough for a while, Deutsche Bank's Woronka said he is bullish on Peloton's fundamentals over the longer term.</p>\n<p>He initiated coverage of Peloton with a buy rating and a 12-month stock price target of $76, which implies nearly about 75% upside from current levels. Woronka said his view is based on an \"unemotional analysis\" of the company's earnings power in a \"normalized, fully-reopened\" economic environment.</p>\n<p>\"[W]hile it's never fun to lead off a buy report with a 'patience required' asterisk of sorts, that's exactly what we find ourselves doing here,\" Woronka wrote in a note to clients.</p>\n<p>As a fundamental analyst, Woronka said he is most interested in looking for \"asymmetrical risk/reward scenarios,\" and that's what he believes Pelton's stock provides at current levels. While there are scenarios in which the stock can still go lower, he believes there are more scenarios that result in even greater upside.</p>\n<p>\"Right now, we believe the market is looking at fitness stocks as an 'either/or' sector; either consumers stay at home to work out or they go back to their favorite pre-COVID-19 fitness facility,\" Woronka wrote. \"In our opinion, that's an oversimplified view of the world; we think the hybrid work model extends to fitness, too, and that [Peloton] has plenty of momentum to regain operationally.\"</p>\n<p>He realizes that sentiment on the stock isn't likely to reflect his bullish view \"until a few quarters of improved execution\" are in the books. But that's where the opportunity for reward lies over a 12-month time horizon.</p>\n<p>Once the stock starts trading on fundamentals again, Woronka believes \"it has quite a bit of room to run.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4216":"消闲设施","PTON":"Peloton Interactive, Inc.","BK4190":"消闲用品","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189576203","content_text":"Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's stock is worth owning for investors with 'patience'\nInvestors should buy Peloton Interactive Inc.'s stock, says Deutsche Bank analyst Chris Woronka, but only those who have the patience to ride out potential volatility, which could last a \"few quarters.\"\nThe at-home fitness company's stock $(PTON)$ slumped 2.0% to close Monday at $43.55, reversing an earlier intraday gain of as much as 4.6%.\nPeloton was viewed as a hot COVID-19-pandemic play last year, with the stock rocketing more than fivefold (up 434%), as gym closures fueled an explosion in the \"work-in\" trend. It's been an entirely different play in 2021, however, as the stock has plunged 71% year to date. It closed Wednesday at $42.25, the lowest price since May 27, 2020.\nIn comparison, shares of fitness center operator Planet Fitness Inc. (PLNT) have gained 3.8% this year and the S&P 500 index has rallied 21%.\nWhile the stock has suffered a \"tough ride\" this year, and the going could still be a bit rough for a while, Deutsche Bank's Woronka said he is bullish on Peloton's fundamentals over the longer term.\nHe initiated coverage of Peloton with a buy rating and a 12-month stock price target of $76, which implies nearly about 75% upside from current levels. Woronka said his view is based on an \"unemotional analysis\" of the company's earnings power in a \"normalized, fully-reopened\" economic environment.\n\"[W]hile it's never fun to lead off a buy report with a 'patience required' asterisk of sorts, that's exactly what we find ourselves doing here,\" Woronka wrote in a note to clients.\nAs a fundamental analyst, Woronka said he is most interested in looking for \"asymmetrical risk/reward scenarios,\" and that's what he believes Pelton's stock provides at current levels. While there are scenarios in which the stock can still go lower, he believes there are more scenarios that result in even greater upside.\n\"Right now, we believe the market is looking at fitness stocks as an 'either/or' sector; either consumers stay at home to work out or they go back to their favorite pre-COVID-19 fitness facility,\" Woronka wrote. \"In our opinion, that's an oversimplified view of the world; we think the hybrid work model extends to fitness, too, and that [Peloton] has plenty of momentum to regain operationally.\"\nHe realizes that sentiment on the stock isn't likely to reflect his bullish view \"until a few quarters of improved execution\" are in the books. But that's where the opportunity for reward lies over a 12-month time horizon.\nOnce the stock starts trading on fundamentals again, Woronka believes \"it has quite a bit of room to run.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608852977,"gmtCreate":1638689039357,"gmtModify":1638693520848,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Nice sharing!","listText":"Nice sharing!","text":"Nice sharing!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608852977","repostId":"2188578706","repostType":2,"repost":{"id":"2188578706","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638577500,"share":"https://www.laohu8.com/m/news/2188578706?lang=&edition=full","pubTime":"2021-12-04 08:25","market":"us","language":"en","title":"DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'","url":"https://stock-news.laohu8.com/highlight/detail?id=2188578706","media":"Dow Jones","summary":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pande","content":"<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 08:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign","BK4528":"SaaS概念","BK4023":"应用软件"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188578706","content_text":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down\nDocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.\nShares of DocuSign $(DOCU)$ fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"\nThe stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.\nThe company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"\nCiti Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.\n\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.\nRadke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.\nEvercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"\nBut the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"\nWhile he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"\nHe cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.\nDocuSign shares are off roughly 52% from their September closing high of $310.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608856246,"gmtCreate":1638688935792,"gmtModify":1638693517962,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608856246","repostId":"2188578706","repostType":2,"repost":{"id":"2188578706","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638577500,"share":"https://www.laohu8.com/m/news/2188578706?lang=&edition=full","pubTime":"2021-12-04 08:25","market":"us","language":"en","title":"DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'","url":"https://stock-news.laohu8.com/highlight/detail?id=2188578706","media":"Dow Jones","summary":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pande","content":"<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 08:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign","BK4528":"SaaS概念","BK4023":"应用软件"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188578706","content_text":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down\nDocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.\nShares of DocuSign $(DOCU)$ fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"\nThe stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.\nThe company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"\nCiti Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.\n\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.\nRadke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.\nEvercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"\nBut the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"\nWhile he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"\nHe cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.\nDocuSign shares are off roughly 52% from their September closing high of $310.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":605697799,"gmtCreate":1639150093330,"gmtModify":1639150180726,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605697799","repostId":"1173242614","repostType":4,"repost":{"id":"1173242614","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639149896,"share":"https://www.laohu8.com/m/news/1173242614?lang=&edition=full","pubTime":"2021-12-10 23:24","market":"us","language":"en","title":"Microsoft stock jumped more than 2% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1173242614","media":"Tiger Newspress","summary":"Microsoft stock jumped more than 2% in morning trading as Microsoft set to win EU antitrust nod for ","content":"<p>Microsoft stock jumped more than 2% in morning trading&nbsp;as&nbsp;Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.</p>\n<p><img src=\"https://static.tigerbbs.com/f2b1206ee31bbf82c8f0f2186cf1d5d0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>U.S. software giant Microsoft Corp&nbsp;is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.</p>\n<p>The deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.</p>\n<p>Microsoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.</p>\n<p>The U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.</p>\n<p>The European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.</p>\n<p>The company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.</p>\n<p>The deal has already received the regulatory green light in the United States and Australia, without remedies given.</p>\n<p>Nuance, known for pioneering speech technology and helping launch Apple Inc's&nbsp;virtual assistant, Siri, serves 77% of U.S. hospitals.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Microsoft stock jumped more than 2% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMicrosoft stock jumped more than 2% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Microsoft stock jumped more than 2% in morning trading&nbsp;as&nbsp;Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.</p>\n<p><img src=\"https://static.tigerbbs.com/f2b1206ee31bbf82c8f0f2186cf1d5d0\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n<p>U.S. software giant Microsoft Corp&nbsp;is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.</p>\n<p>The deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.</p>\n<p>Microsoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.</p>\n<p>The U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.</p>\n<p>The European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.</p>\n<p>The company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.</p>\n<p>The deal has already received the regulatory green light in the United States and Australia, without remedies given.</p>\n<p>Nuance, known for pioneering speech technology and helping launch Apple Inc's&nbsp;virtual assistant, Siri, serves 77% of U.S. hospitals.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MSFT":"微软"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1173242614","content_text":"Microsoft stock jumped more than 2% in morning trading as Microsoft set to win EU antitrust nod for $16 bln Nuance deal, sources said.\n\nU.S. software giant Microsoft Corp is set to secure unconditional EU antitrust approval for its $16 billion bid for artificial intelligence and speech technology firm Nuance Communications Inc, people familiar with the matter said.\nThe deal, the latest in the tech industry, comes amid heightened regulatory scrutiny of takeovers by tech giants and acquisitions where nascent start-ups and potential rivals are shut down.\nMicrosoft announced the deal in April which will boost its presence in cloud solutions for healthcare customers.\nThe U.S. software giant is currently in talks with the British antitrust agency ahead of filing a request for approval of the deal, the sources said.\nThe European Commission, which is scheduled to decide on the deal by Dec. 21, declined to comment. Microsoft also declined to comment.\nThe company is also in preliminary discussions with the UK antitrust agency CMA ahead of a formal request for approval of the deal, the sources said.\nThe deal has already received the regulatory green light in the United States and Australia, without remedies given.\nNuance, known for pioneering speech technology and helping launch Apple Inc's virtual assistant, Siri, serves 77% of U.S. hospitals.","news_type":1},"isVote":1,"tweetType":1,"viewCount":246,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605630899,"gmtCreate":1639150117311,"gmtModify":1639150239790,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Gg.com","listText":"Gg.com","text":"Gg.com","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/605630899","repostId":"1134450838","repostType":4,"repost":{"id":"1134450838","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639148939,"share":"https://www.laohu8.com/m/news/1134450838?lang=&edition=full","pubTime":"2021-12-10 23:08","market":"us","language":"en","title":"Grab shares dropped another 9% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1134450838","media":"Tiger Newspress","summary":"Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.","content":"<p>Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/963eb8dd73ce8daa0d852d63f0bcc276\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab shares dropped another 9% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab shares dropped another 9% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.</p>\n<p><img src=\"https://static.tigerbbs.com/963eb8dd73ce8daa0d852d63f0bcc276\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1134450838","content_text":"Grab shares dropped another 9% in morning trading after falling more than 9% yesterday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":931,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698707452,"gmtCreate":1640526563906,"gmtModify":1640526564008,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698707452","repostId":"2193173436","repostType":4,"repost":{"id":"2193173436","kind":"highlight","pubTimestamp":1640485553,"share":"https://www.laohu8.com/m/news/2193173436?lang=&edition=full","pubTime":"2021-12-26 10:25","market":"us","language":"en","title":"2 Under-the-Radar Biotech Picks to Buy For The Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193173436","media":"Motley Fool","summary":"These quiet biotechs are tightly focused and practically alone in their markets.","content":"<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest <i>downside</i> potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.</p>\n<p>Both companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.</p>\n<h2>1. Catalyst Pharmaceuticals</h2>\n<p><b>Catalyst Pharmaceuticals</b> (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.</p>\n<p>In the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might <a href=\"https://laohu8.com/S/AONE.U\">one</a> day be able to offer it to every LEMS patient in the world.</p>\n<p>Firdapse was originally licensed by Catalyst as part of a deal with <b>BioMarin Pharmaceutical</b>, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.</p>\n<p>So, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.</p>\n<h2>2. Corcept Therapeutics</h2>\n<p><b>Corcept Therapeutics</b> (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.</p>\n<p>Corcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.</p>\n<p>It's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.</p>\n<p>The company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.</p>\n<p>In the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Under-the-Radar Biotech Picks to Buy For The Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Under-the-Radar Biotech Picks to Buy For The Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CORT":"Corcept医疗","BK4211":"区域性银行","BK4139":"生物科技","CPRX":"Catalyst Pharmaceutical Partners","BK4532":"文艺复兴科技持仓","BK4007":"制药","FCF":"第一联邦金融"},"source_url":"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193173436","content_text":"It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest downside potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.\nBoth companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.\n1. Catalyst Pharmaceuticals\nCatalyst Pharmaceuticals (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.\nIn the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might one day be able to offer it to every LEMS patient in the world.\nFirdapse was originally licensed by Catalyst as part of a deal with BioMarin Pharmaceutical, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.\nSo, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.\n2. Corcept Therapeutics\nCorcept Therapeutics (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.\nCorcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.\nIt's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.\nThe company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.\nIn the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":605630262,"gmtCreate":1639150134852,"gmtModify":1639150181825,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605630262","repostId":"1148141788","repostType":4,"repost":{"id":"1148141788","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639147224,"share":"https://www.laohu8.com/m/news/1148141788?lang=&edition=full","pubTime":"2021-12-10 22:40","market":"us","language":"en","title":"Vaccine stocks dropped in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1148141788","media":"Tiger Newspress","summary":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","content":"<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaccine stocks dropped in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaccine stocks dropped in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-10 22:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vaccine stocks dropped in morning trading.Moderna,BioNTech&nbsp;and&nbsp;Novavax&nbsp;fell&nbsp;between 2% and 11%.</p>\n<p><img src=\"https://static.tigerbbs.com/d3f84cfc9f83b59cf14210d41d97111a\" tg-width=\"415\" tg-height=\"302\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1148141788","content_text":"Vaccine stocks dropped in morning trading.Moderna,BioNTech and Novavax fell between 2% and 11%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1379,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698597070,"gmtCreate":1640439401589,"gmtModify":1640439401696,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698597070","repostId":"1122704248","repostType":4,"repost":{"id":"1122704248","kind":"news","pubTimestamp":1640346833,"share":"https://www.laohu8.com/m/news/1122704248?lang=&edition=full","pubTime":"2021-12-24 19:53","market":"us","language":"en","title":"3 Charts to Consider if You Want to Own an EV Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1122704248","media":"Motley Fool","summary":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some","content":"<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.</p>\n<p>Beyond just looking at the exciting new products and potentially huge market,investors should research&nbsp;details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.</p>\n<p><b>Returns have been unpredictable</b></p>\n<p>Many have bought into the EV sector looking for large, market-beating returns. While shares of EV leader<b>Tesla</b>(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/628cf15ff39a9f1a896ba56a7db9020d\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>DATA BYYCHARTS.</span></p>\n<p>Even the strong returns from Tesla and&nbsp;<b>Lucid Group</b>(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.<b>Lordstown Motors</b>(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.</p>\n<p><b>There's plenty of demand</b></p>\n<p>Just looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a2201193c16f33bc21f52f5aacebbea\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.</span></p>\n<p>Tesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent&nbsp;market capitalizations&nbsp;of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.</p>\n<p><b>Profitability will take time</b></p>\n<p>Investors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32eab03a7b97ed8deb8757e127924d51\" tg-width=\"700\" tg-height=\"495\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.</span></p>\n<p>Tesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .</p>\n<p>BYD is perhaps a less well-known Chinese EV company, and it sells more than just&nbsp;electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.</p>\n<p>Lucid and&nbsp;<b>Rivian Automotive</b>(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Charts to Consider if You Want to Own an EV Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Charts to Consider if You Want to Own an EV Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 19:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏汽车","LCID":"Lucid Group Inc","TSLA":"特斯拉","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122704248","content_text":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.\nBeyond just looking at the exciting new products and potentially huge market,investors should research details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.\nReturns have been unpredictable\nMany have bought into the EV sector looking for large, market-beating returns. While shares of EV leaderTesla(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:\nDATA BYYCHARTS.\nEven the strong returns from Tesla and Lucid Group(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers Nio(NYSE:NIO) and XPeng(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.Lordstown Motors(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.\nThere's plenty of demand\nJust looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.\nTesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent market capitalizations of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.\nProfitability will take time\nInvestors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.\nTesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .\nBYD is perhaps a less well-known Chinese EV company, and it sells more than just electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.\nLucid and Rivian Automotive(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602731338,"gmtCreate":1639064385388,"gmtModify":1639065338695,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Gg.com","listText":"Gg.com","text":"Gg.com","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602731338","repostId":"1196130142","repostType":4,"repost":{"id":"1196130142","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1639062546,"share":"https://www.laohu8.com/m/news/1196130142?lang=&edition=full","pubTime":"2021-12-09 23:09","market":"us","language":"en","title":"Grab stock dropped more than 6% in morning trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1196130142","media":"Tiger Newspress","summary":"Grab Holdings stock dropped more than 6% in morning trading.","content":"<p>Grab Holdings stock dropped more than 6% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1c84529a60ffcf4e7ba53b126b147d9\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grab stock dropped more than 6% in morning trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrab stock dropped more than 6% in morning trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-09 23:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Grab Holdings stock dropped more than 6% in morning trading.</p>\n<p><img src=\"https://static.tigerbbs.com/f1c84529a60ffcf4e7ba53b126b147d9\" tg-width=\"840\" tg-height=\"470\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GRAB":"Grab Holdings"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196130142","content_text":"Grab Holdings stock dropped more than 6% in morning trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":323,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608852977,"gmtCreate":1638689039357,"gmtModify":1638693520848,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Nice sharing!","listText":"Nice sharing!","text":"Nice sharing!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608852977","repostId":"2188578706","repostType":2,"repost":{"id":"2188578706","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638577500,"share":"https://www.laohu8.com/m/news/2188578706?lang=&edition=full","pubTime":"2021-12-04 08:25","market":"us","language":"en","title":"DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'","url":"https://stock-news.laohu8.com/highlight/detail?id=2188578706","media":"Dow Jones","summary":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pande","content":"<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 08:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign","BK4528":"SaaS概念","BK4023":"应用软件"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188578706","content_text":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down\nDocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.\nShares of DocuSign $(DOCU)$ fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"\nThe stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.\nThe company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"\nCiti Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.\n\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.\nRadke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.\nEvercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"\nBut the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"\nWhile he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"\nHe cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.\nDocuSign shares are off roughly 52% from their September closing high of $310.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608856246,"gmtCreate":1638688935792,"gmtModify":1638693517962,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍👍","listText":"👍👍","text":"👍👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608856246","repostId":"2188578706","repostType":2,"repost":{"id":"2188578706","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638577500,"share":"https://www.laohu8.com/m/news/2188578706?lang=&edition=full","pubTime":"2021-12-04 08:25","market":"us","language":"en","title":"DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'","url":"https://stock-news.laohu8.com/highlight/detail?id=2188578706","media":"Dow Jones","summary":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pande","content":"<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDocuSign stock craters to worst day on record after 'one of the biggest SaaS whiffs in recent memory'\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-04 08:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down</p>\n<p>DocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.</p>\n<p>Shares of DocuSign <a href=\"https://laohu8.com/S/DOCU\">$(DOCU)$</a> fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"</p>\n<p>The stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&amp;P 500 index has rallied 21% this year after climbing 16% last year.</p>\n<p>The company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"</p>\n<p>Citi Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.</p>\n<p>\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.</p>\n<p>Radke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.</p>\n<p>Evercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"</p>\n<p>But the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"</p>\n<p>While he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"</p>\n<p>He cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.</p>\n<p>DocuSign shares are off roughly 52% from their September closing high of $310.05.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DOCU":"Docusign","BK4528":"SaaS概念","BK4023":"应用软件"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2188578706","content_text":"Electronic-signature company drops more than 40%, shedding nearly $20 billion of market cap as pandemic boom in e-signature sales slows down\nDocuSign Inc. emerged as a hot pandemic stock play last year as it benefited from the need for digital contract tools, but the company lost more than 40% of its valuation Friday after suggesting the pandemic-induced demand boom is waning.\nShares of DocuSign $(DOCU)$ fell 42.2% Friday, by far their steepest single-day percentage decline on record, wiping away roughly $19.4 billion worth of market capitalization. DocuSign issued earnings Thursday evening with a disappointing billings outlook, and Chief Executive Dan Springer called out a \"return to more normalized buying patterns\" following a stretch of \"accelerated growth.\"\nThe stock nearly tripled in 2020, pushing its market cap higher than $40 billion, but is now down 39.2% this year. In comparison, the S&P 500 index has rallied 21% this year after climbing 16% last year.\nThe company's report served as \"a good reminder that even outstanding companies take their proverbial eye off the sales ball,\" Needham analyst Scott Berg wrote in a note downgrading DocuSign's stock to hold from buy. While DocuSign announced that it would be changing some elements of its sales organization, Berg said he has found that \"fixing these sales issues often requires several quarters.\"\nCiti Research analyst Tyler Radke wrote that DocuSign delivered \"one of the biggest SaaS [software-as-a-service] whiffs in recent memory with total billings growth of 28% significantly below [the] 34% guide\" during the fiscal third quarter. DocuSign's billings outlook for the fiscal fourth quarter was 22% at the midpoint, which came in significantly below the 32% consensus figure Radke cited in his note to clients.\n\"With a largely resilient performance vs [work-from-home] peers over the last two quarters, we are surprised that DOCU is seeing significant customer behavior/execution issues cropping up now, and in this magnitude,\" he continued.\nRadke called the report a \"thesis shifter,\" though he kept his buy rating on the stock, arguing that DocuSign has a \"first-mover advantage\" in its domain and that there are \"few signs\" that people are shifting back to manual agreements. He cut his target price to $231 from $389.\nEvercore ISI analyst Kirk Materne wrote that while DocuSign faced difficult comparisons in its most recent quarter, the company \"simply misread the market in terms of demand and that led to a faster than expected deceleration in billings growth.\"\nBut the stock's sharp move downward indicates that \"the damage is essentially done as it relates to the quarter,\" he wrote. Further, after speaking with DocuSign's management team, Materne believes that DocuSign's fiscal fourth-quarter billing outlook \"assumes no improvement in demand [generation] vs. 3Q, which could prove conservative.\"\nWhile he called the stock's selloff \"a bit overdone,\" Materne admitted that \"the reality is this stock just went from a story where investors were thinking about durable growth being in the 30%'s to being in the 20%'s and that's going to create a pretty material de-rate.\"\nHe cut his price target to $200 from $320, writing that \"until DOCU can show that it can generate, not just fulfill, demand on a regular basis, the multiple is capped.\" Materne kept an outperform rating on the stock, citing the long-term potential of e-signature technology especially in markets like government where DocuSign is \"very early\" in its penetration.\nDocuSign shares are off roughly 52% from their September closing high of $310.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696211249,"gmtCreate":1640701604587,"gmtModify":1640701625883,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696211249","repostId":"1146958718","repostType":4,"isVote":1,"tweetType":1,"viewCount":2089,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696211019,"gmtCreate":1640701555641,"gmtModify":1640701555703,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696211019","repostId":"2194343800","repostType":4,"isVote":1,"tweetType":1,"viewCount":1056,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696935515,"gmtCreate":1640595274071,"gmtModify":1640595291523,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/696935515","repostId":"1160732619","repostType":4,"isVote":1,"tweetType":1,"viewCount":1510,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698707893,"gmtCreate":1640526505470,"gmtModify":1640526505470,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Good read!","listText":"Good read!","text":"Good read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698707893","repostId":"2193173436","repostType":4,"repost":{"id":"2193173436","kind":"highlight","pubTimestamp":1640485553,"share":"https://www.laohu8.com/m/news/2193173436?lang=&edition=full","pubTime":"2021-12-26 10:25","market":"us","language":"en","title":"2 Under-the-Radar Biotech Picks to Buy For The Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2193173436","media":"Motley Fool","summary":"These quiet biotechs are tightly focused and practically alone in their markets.","content":"<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest <i>downside</i> potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.</p>\n<p>Both companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.</p>\n<h2>1. Catalyst Pharmaceuticals</h2>\n<p><b>Catalyst Pharmaceuticals</b> (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.</p>\n<p>In the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might <a href=\"https://laohu8.com/S/AONE.U\">one</a> day be able to offer it to every LEMS patient in the world.</p>\n<p>Firdapse was originally licensed by Catalyst as part of a deal with <b>BioMarin Pharmaceutical</b>, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.</p>\n<p>So, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.</p>\n<h2>2. Corcept Therapeutics</h2>\n<p><b>Corcept Therapeutics</b> (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.</p>\n<p>Corcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.</p>\n<p>It's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.</p>\n<p>The company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.</p>\n<p>In the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>2 Under-the-Radar Biotech Picks to Buy For The Long Haul</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n2 Under-the-Radar Biotech Picks to Buy For The Long Haul\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-26 10:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CORT":"Corcept医疗","BK4211":"区域性银行","BK4139":"生物科技","CPRX":"Catalyst Pharmaceutical Partners","BK4532":"文艺复兴科技持仓","BK4007":"制药","FCF":"第一联邦金融"},"source_url":"https://www.fool.com/investing/2021/12/24/2-under-the-radar-biotech-picks-buy-for-long-term/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2193173436","content_text":"It can be hard to find biotechs that are investment-grade, especially when you're not interested in taking home a frothy bubbling cauldron of risk. Many early-stage companies with the highest upside potential also have the highest downside potential, and few are safe from competitors' efforts to make drugs that address the same conditions. And that's why it pays to know about biotechs that have succeeded in staking out a niche where they can flourish for a long time.\nBoth companies I'll discuss today have profit margins near 30%, and neither has much in the way of debt. The pair are also highly differentiated, targeting uncommon diseases and indications that nobody else is working on. And by the looks of it, they both have staying power, so they could be ripe for a long-term hold. Join me as I analyze why.\n1. Catalyst Pharmaceuticals\nCatalyst Pharmaceuticals (NASDAQ:CPRX) makes a drug called Firdapse, which treats Lambert-Eaton myasthenic syndrome (LEMS), a rare autoimmune disease that occurs in perhaps 1 in 100,000 people. With such an uncommon target market and no competitors, Catalyst is positioned to keep helping its small group of patients for years and years to come.\nIn the last three years alone, Catalyst's quarterly revenue from Firdapse has grown by 188.8%, reaching $35.9 million in the third quarter. To prepare for the drug's eventual loss of exclusivity, the company is already developing a replacement which will be more convenient for patients while also working on an expanded approval in pediatrics. In the meanwhile, new patients are still enrolling to take the drug for the first time, and it's possible that the business might one day be able to offer it to every LEMS patient in the world.\nFirdapse was originally licensed by Catalyst as part of a deal with BioMarin Pharmaceutical, which now owns a portion of the company and controls the rights to commercialize the drug outside of the U.S. As part of the terms of the collaboration, Catalyst is now eligible to try to commercialize Firdapse in Japan; it's now pursuing that by starting a small registrational study in early 2022. If it succeeds in Japan, it'll then have the chance to seek approval in other global markets according to the deal, but the process will probably take a few years.\nSo, people who invest today will have the benefit of capturing the upside from whichever regions Firdapse can be commercialized in outside the U.S. And, assuming Catalyst continues to be the only player in the LEMS therapeutics market, it's hard to see how things could go wrong.\n2. Corcept Therapeutics\nCorcept Therapeutics (NASDAQ:CORT) is, to my knowledge, the world's only profitable and publicly traded biotech focused exclusively on developing therapies targeting the hormone known as cortisol. Having such a narrow focus ensures that less-differentiated competitors are unlikely to be as skilled when attempting to develop medicines using the same cortisol-based approach, and it also guarantees that Corcept is the only game in town when specific populations of patients are seeking treatment.\nCorcept makes a drug called Korlym that's approved in the U.S. to treat hyperglycemia in people with endogenous Cushing's syndrome. Sales of Korlym are responsible for driving the company's $352.89 million in trailing revenue, not to mention its rising quarterly free cash flow (FCF), which has grown by 107.2% over the last three years.\nIt's also developing a next-gen therapy for the same purpose called relacorilant, which is currently in phase 3 trials. If it's approved, relacorilant will mitigate the looming risk of generics stealing market share from Korlym, which is important given that several manufacturers are in the process of developing their own versions of the drug.\nThe company believes that cortisol-based medicines could also be useful in treating a slew of other conditions, including ovarian cancer, prostate cancer, obesity, hypertension, and even alcohol dependence.\nIn the long term, progress in its therapy projects in these indications could drive colossal returns for people who buy the stock now. Until then, Corcept will be sustained by its profitable sales of Korlym, which in turn massively reduces the risk that investors will be taking on. Even if Corcept will never be a household name, it'll be making money and investing for the future for years to come -- and if competitors ever come knocking, they'll be fighting on its home turf.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1697,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698594486,"gmtCreate":1640439305692,"gmtModify":1640439305763,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great Read!","listText":"Great Read!","text":"Great Read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698594486","repostId":"1122704248","repostType":4,"repost":{"id":"1122704248","kind":"news","pubTimestamp":1640346833,"share":"https://www.laohu8.com/m/news/1122704248?lang=&edition=full","pubTime":"2021-12-24 19:53","market":"us","language":"en","title":"3 Charts to Consider if You Want to Own an EV Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1122704248","media":"Motley Fool","summary":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some","content":"<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.</p>\n<p>Beyond just looking at the exciting new products and potentially huge market,investors should research&nbsp;details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.</p>\n<p><b>Returns have been unpredictable</b></p>\n<p>Many have bought into the EV sector looking for large, market-beating returns. While shares of EV leader<b>Tesla</b>(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/628cf15ff39a9f1a896ba56a7db9020d\" tg-width=\"720\" tg-height=\"387\" width=\"100%\" height=\"auto\"><span>DATA BYYCHARTS.</span></p>\n<p>Even the strong returns from Tesla and&nbsp;<b>Lucid Group</b>(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers&nbsp;<b>Nio</b>(NYSE:NIO)&nbsp;and&nbsp;<b>XPeng</b>(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.<b>Lordstown Motors</b>(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.</p>\n<p><b>There's plenty of demand</b></p>\n<p>Just looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/7a2201193c16f33bc21f52f5aacebbea\" tg-width=\"700\" tg-height=\"467\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.</span></p>\n<p>Tesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent&nbsp;market capitalizations&nbsp;of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.</p>\n<p><b>Profitability will take time</b></p>\n<p>Investors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/32eab03a7b97ed8deb8757e127924d51\" tg-width=\"700\" tg-height=\"495\" width=\"100%\" height=\"auto\"><span>DATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.</span></p>\n<p>Tesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .</p>\n<p>BYD is perhaps a less well-known Chinese EV company, and it sells more than just&nbsp;electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.</p>\n<p>Lucid and&nbsp;<b>Rivian Automotive</b>(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Charts to Consider if You Want to Own an EV Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Charts to Consider if You Want to Own an EV Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-24 19:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏汽车","LCID":"Lucid Group Inc","TSLA":"特斯拉","RIVN":"Rivian Automotive, Inc."},"source_url":"https://www.fool.com/investing/2021/12/24/3-charts-to-consider-to-own-an-ev-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122704248","content_text":"There's been a lot of investor excitement about electric vehicle (EV) companies. And gains from some stocks have been exceptional over the last two years. Now, the landscape for the sector seems to be clearing so investors can get a better idea of who the players are, and over what time frame EV makers will be bringing out new offerings.\nBeyond just looking at the exciting new products and potentially huge market,investors should research details that will help compare and contrast the EV makers. If you're interested in diving in now, the three charts below will provide a look at some data worth considering before you make an investment.\nReturns have been unpredictable\nMany have bought into the EV sector looking for large, market-beating returns. While shares of EV leaderTesla(NASDAQ:TSLA)skyrocketed last year, as the field of publicly traded names has grown, returns have been inconsistent. And investors need to be prepared for plenty of volatility along the way. The chart below shows the most recent six-month returns from a mix of U.S.- and China-based EV makers:\nDATA BYYCHARTS.\nEven the strong returns from Tesla and Lucid Group(NASDAQ:LCID)stocks have included big swings in just the past two months. And though Chinese EV makers Nio(NYSE:NIO) and XPeng(NYSE:XPEV)have been growing sales quickly, their stocks have backtracked since June 2021.Lordstown Motors(NASDAQ:RIDE), maker of the Endurance all-electric work truck, has struggled, and shareholders have paid the price this year. The lesson is that there will be winners and losers, and EV stock moves can be quick and extreme.\nThere's plenty of demand\nJust looking at share-price movement doesn't tell the full story, of course. While Nio and XPeng shares haven't moved higher in the last half-year, both company's sales skyrocketed over the first nine months of 2021, as shown below:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.*XPENG 2021 COMPARISON WITH FINAL THREE QUARTERS OF 2020.\nTesla has almost doubled its deliveries over the first nine months of 2021 compared to the year-ago period. But XPeng andNio deliveries are growing much faster, though the two Chinese companies are growing off of a much smaller base. And as both are already richly valued, with recent market capitalizations of around $36 billion and $48 billion, respectively, investors have sold off shares in recent months. Global demand is strong and growing, but that won't automatically result in growing share prices.\nProfitability will take time\nInvestors in any business need to focus on the bottom line. Early stage growth companies aren't necessarily expected to become profitable quickly, however. Especially with a high-fixed-cost business like automotive manufacturing, profits will only come with scale. As the chart below shows, few EV makers are bringing in profits yet:\nDATA SOURCE: COMPANY FINANCIAL FILINGS. CHART BY AUTHOR.\nTesla led the industry with a reported profit of more than $1.6 billion in the third quarter of 2021 .\nBYD is perhaps a less well-known Chinese EV company, and it sells more than just electric cars; it also makes batteries, electric buses, and traditional internal combustion vehicles. But its \"new energy vehicles\" -- which include plug-in hybrid electrics -- made up more than 90% of the nearly 100,000 new energy passenger vehicles it delivered in November.\nLucid and Rivian Automotive(NASDAQ:RIVN)are getting a lot of attention recently, but they've barely started shipping product; the losses there will continue for some time until those companies reach scale. Investors hope that Nio and XPeng reach profitability soon, as both are growing sales and expanding product offerings. But investors interested in the sector need to be prepared for a long road before profitability can be expected.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1729,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698847627,"gmtCreate":1640353060903,"gmtModify":1640353060977,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/698847627","repostId":"1103939939","repostType":4,"isVote":1,"tweetType":1,"viewCount":1177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":602739367,"gmtCreate":1639064215751,"gmtModify":1639064832446,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Ok!","listText":"Ok!","text":"Ok!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602739367","repostId":"2189667447","repostType":2,"repost":{"id":"2189667447","kind":"highlight","pubTimestamp":1639022040,"share":"https://www.laohu8.com/m/news/2189667447?lang=&edition=full","pubTime":"2021-12-09 11:54","market":"us","language":"en","title":"3 Growth Stocks Down Over 50% To Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2189667447","media":"Motley Fool","summary":"The stock market is offering long-term investors an opportunity to buy these excellent businesses at a discount.","content":"<p>Investing in stocks for the long term can be an effective way to build wealth. However, the path to increasing stock values is rarely an upward straight line. More frequently, it is charted with several peaks and valleys. Long-term investors with the courage and discipline to hold or buy stocks during major crashes are sometimes rewarded with exponential gains.</p>\n<p>If you have extra cash you will not need for several years for life's necessities, you can buy stocks with good long-term prospects that are down due to short-term causes. <b>Chegg</b> (NYSE:CHGG), <b>Peloton</b> (NASDAQ:PTON), and <b>Skillz</b> (NYSE:SKLZ) are three stocks you can buy right now that are down over 50% while their long-term prospects remain intact.</p>\n<h2>Chegg</h2>\n<p>Chegg is an education technology company with a subscription business model. It caters primarily to college students by offering help with course curriculum. Chegg's platform has over 70 million step-by-step solutions to answers that students may have difficulty understanding. Chegg has built this database through student requests. In addition to having full access to existing content, students can ask 20 questions per month answered by subject-matter experts with their subscription. These questions and answers are then added to the database for all students to view.</p>\n<p>That's a lucrative business model because Chegg pays for that content once and gets the benefits for several years. The college curriculum does not change much over the years, so the assets pay dividends for decades. Chegg is already starting to capture the benefits of scaling to a more significant subscriber and revenue base. Indeed, from 2015 to 2020, operating profit grew from a loss of $57 million to a positive $57 million.</p>\n<p>Nevertheless, the stock is down 67.5% in 2021, with most losses coming after Nov. 1. That's when the company lowered the forecast for the rest of the fiscal year, citing a significant drop-off in student enrollment.</p>\n<h2>Peloton</h2>\n<p>Peloton sells interactive exercise equipment and a subscription to live and recorded exercise classes. The company was already gaining popularity before the pandemic increased the demand for in-home exercise equipment. As a result, revenue more than doubled to $4 billion in fiscal 2021.</p>\n<p>Once a customer signs up, they tend to stick around. Peloton boasted a membership retention rate of 92% in its most recent quarter ended Sept. 30. The company has a robust selection of live and recorded classes and makes members feel part of a community.</p>\n<p>Peloton had 2.5 million connected fitness subscribers at the end of the quarter, and management is forecasting that it will grow to 3.4 million by the end of fiscal 2022. Still, that would be a small part of the number of people that regularly exercise -- leaving Peloton with a long runway for growth.</p>\n<p>Peloton's stock is down 72% in 2021, mainly because economic reopening slowed the demand for in-home exercise equipment. That being said, Peloton's sales are growing on top of last years' elevated levels.</p>\n<h2>Skillz</h2>\n<p>Skillz is a gaming company with a unique twist: It allows contestants to wager on their games and doles out cash prizes to winners. The company's business is not considered gambling because the games on its site are based on skill. In other words, winners win because they are better at the game and not because of chance. Of course, if you have money on the line, you engage with the games more seriously than you would otherwise.</p>\n<p>In its most recent quarter,&nbsp;the company boasted 0.51 million monthly active users, up from 0.35 million in the year before. Still, the growth is not pleasing investors because the company is spending so heavily on sales and marketing. Skillz spent 112% of revenue on sales and marketing in its most recent quarter. Investors feel it should be getting better results from that spending. The stock is down 57.8% in 2021.</p>\n<p>Each of these three stocks is down big because of short-term catalysts. That could be an excellent buying opportunity for long-term investors who want to buy these growth stocks at more than 50% off their highs.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Growth Stocks Down Over 50% To Buy Now</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Growth Stocks Down Over 50% To Buy Now\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 11:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/08/3-growth-stocks-down-over-50-to-buy-now/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investing in stocks for the long term can be an effective way to build wealth. However, the path to increasing stock values is rarely an upward straight line. More frequently, it is charted with ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/08/3-growth-stocks-down-over-50-to-buy-now/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CHGG":"Chegg Inc","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","SKLZ":"Skillz Inc","BK4204":"教育服务","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","PTON":"Peloton Interactive, Inc.","BK4085":"互动家庭娱乐","BK4190":"消闲用品"},"source_url":"https://www.fool.com/investing/2021/12/08/3-growth-stocks-down-over-50-to-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189667447","content_text":"Investing in stocks for the long term can be an effective way to build wealth. However, the path to increasing stock values is rarely an upward straight line. More frequently, it is charted with several peaks and valleys. Long-term investors with the courage and discipline to hold or buy stocks during major crashes are sometimes rewarded with exponential gains.\nIf you have extra cash you will not need for several years for life's necessities, you can buy stocks with good long-term prospects that are down due to short-term causes. Chegg (NYSE:CHGG), Peloton (NASDAQ:PTON), and Skillz (NYSE:SKLZ) are three stocks you can buy right now that are down over 50% while their long-term prospects remain intact.\nChegg\nChegg is an education technology company with a subscription business model. It caters primarily to college students by offering help with course curriculum. Chegg's platform has over 70 million step-by-step solutions to answers that students may have difficulty understanding. Chegg has built this database through student requests. In addition to having full access to existing content, students can ask 20 questions per month answered by subject-matter experts with their subscription. These questions and answers are then added to the database for all students to view.\nThat's a lucrative business model because Chegg pays for that content once and gets the benefits for several years. The college curriculum does not change much over the years, so the assets pay dividends for decades. Chegg is already starting to capture the benefits of scaling to a more significant subscriber and revenue base. Indeed, from 2015 to 2020, operating profit grew from a loss of $57 million to a positive $57 million.\nNevertheless, the stock is down 67.5% in 2021, with most losses coming after Nov. 1. That's when the company lowered the forecast for the rest of the fiscal year, citing a significant drop-off in student enrollment.\nPeloton\nPeloton sells interactive exercise equipment and a subscription to live and recorded exercise classes. The company was already gaining popularity before the pandemic increased the demand for in-home exercise equipment. As a result, revenue more than doubled to $4 billion in fiscal 2021.\nOnce a customer signs up, they tend to stick around. Peloton boasted a membership retention rate of 92% in its most recent quarter ended Sept. 30. The company has a robust selection of live and recorded classes and makes members feel part of a community.\nPeloton had 2.5 million connected fitness subscribers at the end of the quarter, and management is forecasting that it will grow to 3.4 million by the end of fiscal 2022. Still, that would be a small part of the number of people that regularly exercise -- leaving Peloton with a long runway for growth.\nPeloton's stock is down 72% in 2021, mainly because economic reopening slowed the demand for in-home exercise equipment. That being said, Peloton's sales are growing on top of last years' elevated levels.\nSkillz\nSkillz is a gaming company with a unique twist: It allows contestants to wager on their games and doles out cash prizes to winners. The company's business is not considered gambling because the games on its site are based on skill. In other words, winners win because they are better at the game and not because of chance. Of course, if you have money on the line, you engage with the games more seriously than you would otherwise.\nIn its most recent quarter, the company boasted 0.51 million monthly active users, up from 0.35 million in the year before. Still, the growth is not pleasing investors because the company is spending so heavily on sales and marketing. Skillz spent 112% of revenue on sales and marketing in its most recent quarter. Investors feel it should be getting better results from that spending. The stock is down 57.8% in 2021.\nEach of these three stocks is down big because of short-term catalysts. That could be an excellent buying opportunity for long-term investors who want to buy these growth stocks at more than 50% off their highs.","news_type":1},"isVote":1,"tweetType":1,"viewCount":411,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":608667276,"gmtCreate":1638717131616,"gmtModify":1638756438111,"author":{"id":"3581994349439737","authorId":"3581994349439737","name":"MrMumu","avatar":"https://static.tigerbbs.com/0d8c5228565efd9e0776c8f9a1e9f515","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3581994349439737","idStr":"3581994349439737"},"themes":[],"htmlText":"Great sharing!","listText":"Great sharing!","text":"Great sharing!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/608667276","repostId":"2189576203","repostType":4,"repost":{"id":"2189576203","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1638691560,"share":"https://www.laohu8.com/m/news/2189576203?lang=&edition=full","pubTime":"2021-12-05 16:06","market":"us","language":"en","title":"Peloton stock is a buy, but with an 'asterisk', analyst says","url":"https://stock-news.laohu8.com/highlight/detail?id=2189576203","media":"Dow Jones","summary":"Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's","content":"<p>Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's stock is worth owning for investors with 'patience'</p>\n<p>Investors should buy Peloton Interactive Inc.'s stock, says Deutsche Bank analyst Chris Woronka, but only those who have the patience to ride out potential volatility, which could last a \"few quarters.\"</p>\n<p>The at-home fitness company's stock <a href=\"https://laohu8.com/S/PTON\">$(PTON)$</a> slumped 2.0% to close Monday at $43.55, reversing an earlier intraday gain of as much as 4.6%.</p>\n<p>Peloton was viewed as a hot COVID-19-pandemic play last year, with the stock rocketing more than fivefold (up 434%), as gym closures fueled an explosion in the \"work-in\" trend. It's been an entirely different play in 2021, however, as the stock has plunged 71% year to date. It closed Wednesday at $42.25, the lowest price since May 27, 2020.</p>\n<p>In comparison, shares of fitness center operator <a href=\"https://laohu8.com/S/PLNT\">Planet Fitness Inc</a>. (PLNT) have gained 3.8% this year and the S&amp;P 500 index has rallied 21%.</p>\n<p>While the stock has suffered a \"tough ride\" this year, and the going could still be a bit rough for a while, Deutsche Bank's Woronka said he is bullish on Peloton's fundamentals over the longer term.</p>\n<p>He initiated coverage of Peloton with a buy rating and a 12-month stock price target of $76, which implies nearly about 75% upside from current levels. Woronka said his view is based on an \"unemotional analysis\" of the company's earnings power in a \"normalized, fully-reopened\" economic environment.</p>\n<p>\"[W]hile it's never fun to lead off a buy report with a 'patience required' asterisk of sorts, that's exactly what we find ourselves doing here,\" Woronka wrote in a note to clients.</p>\n<p>As a fundamental analyst, Woronka said he is most interested in looking for \"asymmetrical risk/reward scenarios,\" and that's what he believes Pelton's stock provides at current levels. While there are scenarios in which the stock can still go lower, he believes there are more scenarios that result in even greater upside.</p>\n<p>\"Right now, we believe the market is looking at fitness stocks as an 'either/or' sector; either consumers stay at home to work out or they go back to their favorite pre-COVID-19 fitness facility,\" Woronka wrote. \"In our opinion, that's an oversimplified view of the world; we think the hybrid work model extends to fitness, too, and that [Peloton] has plenty of momentum to regain operationally.\"</p>\n<p>He realizes that sentiment on the stock isn't likely to reflect his bullish view \"until a few quarters of improved execution\" are in the books. But that's where the opportunity for reward lies over a 12-month time horizon.</p>\n<p>Once the stock starts trading on fundamentals again, Woronka believes \"it has quite a bit of room to run.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peloton stock is a buy, but with an 'asterisk', analyst says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeloton stock is a buy, but with an 'asterisk', analyst says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-12-05 16:06</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's stock is worth owning for investors with 'patience'</p>\n<p>Investors should buy Peloton Interactive Inc.'s stock, says Deutsche Bank analyst Chris Woronka, but only those who have the patience to ride out potential volatility, which could last a \"few quarters.\"</p>\n<p>The at-home fitness company's stock <a href=\"https://laohu8.com/S/PTON\">$(PTON)$</a> slumped 2.0% to close Monday at $43.55, reversing an earlier intraday gain of as much as 4.6%.</p>\n<p>Peloton was viewed as a hot COVID-19-pandemic play last year, with the stock rocketing more than fivefold (up 434%), as gym closures fueled an explosion in the \"work-in\" trend. It's been an entirely different play in 2021, however, as the stock has plunged 71% year to date. It closed Wednesday at $42.25, the lowest price since May 27, 2020.</p>\n<p>In comparison, shares of fitness center operator <a href=\"https://laohu8.com/S/PLNT\">Planet Fitness Inc</a>. (PLNT) have gained 3.8% this year and the S&amp;P 500 index has rallied 21%.</p>\n<p>While the stock has suffered a \"tough ride\" this year, and the going could still be a bit rough for a while, Deutsche Bank's Woronka said he is bullish on Peloton's fundamentals over the longer term.</p>\n<p>He initiated coverage of Peloton with a buy rating and a 12-month stock price target of $76, which implies nearly about 75% upside from current levels. Woronka said his view is based on an \"unemotional analysis\" of the company's earnings power in a \"normalized, fully-reopened\" economic environment.</p>\n<p>\"[W]hile it's never fun to lead off a buy report with a 'patience required' asterisk of sorts, that's exactly what we find ourselves doing here,\" Woronka wrote in a note to clients.</p>\n<p>As a fundamental analyst, Woronka said he is most interested in looking for \"asymmetrical risk/reward scenarios,\" and that's what he believes Pelton's stock provides at current levels. While there are scenarios in which the stock can still go lower, he believes there are more scenarios that result in even greater upside.</p>\n<p>\"Right now, we believe the market is looking at fitness stocks as an 'either/or' sector; either consumers stay at home to work out or they go back to their favorite pre-COVID-19 fitness facility,\" Woronka wrote. \"In our opinion, that's an oversimplified view of the world; we think the hybrid work model extends to fitness, too, and that [Peloton] has plenty of momentum to regain operationally.\"</p>\n<p>He realizes that sentiment on the stock isn't likely to reflect his bullish view \"until a few quarters of improved execution\" are in the books. But that's where the opportunity for reward lies over a 12-month time horizon.</p>\n<p>Once the stock starts trading on fundamentals again, Woronka believes \"it has quite a bit of room to run.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4216":"消闲设施","PTON":"Peloton Interactive, Inc.","BK4190":"消闲用品","BK4566":"资本集团","BK4532":"文艺复兴科技持仓","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2189576203","content_text":"Deutsche Bank's Chris Woronka said his 'unemotional analysis' suggests the at-home fitness company's stock is worth owning for investors with 'patience'\nInvestors should buy Peloton Interactive Inc.'s stock, says Deutsche Bank analyst Chris Woronka, but only those who have the patience to ride out potential volatility, which could last a \"few quarters.\"\nThe at-home fitness company's stock $(PTON)$ slumped 2.0% to close Monday at $43.55, reversing an earlier intraday gain of as much as 4.6%.\nPeloton was viewed as a hot COVID-19-pandemic play last year, with the stock rocketing more than fivefold (up 434%), as gym closures fueled an explosion in the \"work-in\" trend. It's been an entirely different play in 2021, however, as the stock has plunged 71% year to date. It closed Wednesday at $42.25, the lowest price since May 27, 2020.\nIn comparison, shares of fitness center operator Planet Fitness Inc. (PLNT) have gained 3.8% this year and the S&P 500 index has rallied 21%.\nWhile the stock has suffered a \"tough ride\" this year, and the going could still be a bit rough for a while, Deutsche Bank's Woronka said he is bullish on Peloton's fundamentals over the longer term.\nHe initiated coverage of Peloton with a buy rating and a 12-month stock price target of $76, which implies nearly about 75% upside from current levels. Woronka said his view is based on an \"unemotional analysis\" of the company's earnings power in a \"normalized, fully-reopened\" economic environment.\n\"[W]hile it's never fun to lead off a buy report with a 'patience required' asterisk of sorts, that's exactly what we find ourselves doing here,\" Woronka wrote in a note to clients.\nAs a fundamental analyst, Woronka said he is most interested in looking for \"asymmetrical risk/reward scenarios,\" and that's what he believes Pelton's stock provides at current levels. While there are scenarios in which the stock can still go lower, he believes there are more scenarios that result in even greater upside.\n\"Right now, we believe the market is looking at fitness stocks as an 'either/or' sector; either consumers stay at home to work out or they go back to their favorite pre-COVID-19 fitness facility,\" Woronka wrote. \"In our opinion, that's an oversimplified view of the world; we think the hybrid work model extends to fitness, too, and that [Peloton] has plenty of momentum to regain operationally.\"\nHe realizes that sentiment on the stock isn't likely to reflect his bullish view \"until a few quarters of improved execution\" are in the books. But that's where the opportunity for reward lies over a 12-month time horizon.\nOnce the stock starts trading on fundamentals again, Woronka believes \"it has quite a bit of room to run.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":332,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}